Given the growing evidence that obesity is associated with increased cardiovascular risk, a recent study assessed the impact of semaglutide on cardiovascular outcomes in patients who are overweight or obese but do not have diabetes. Not only did semaglutide reduce the risk of cardiovascular death, myocardial infarction, and stroke by 20 percent, but it also significantly reduced the risk of developing diabetes. Dive further into the findings and implications with Dr. Carol Wysham and study author Dr. Michael Lincoff.
The SEARCH for Diabetes in Asian and Pacific-Islander Youth
Multiple Choice: Customizing Insulin Therapy
Side by Side: Diabetes Patients' Emotional & Behavioral Support
Effects of Diabetes on the Musculoskeletal System
Clinical Care Implications of ALLHAT
The Potential of Immunotherapy in Type 1 Diabetes
Emerging Insulin Pump Technology
A Multidisciplinary Approach to Sexual Medicine in Diabetes
Novel Pilot Programs in the Prevention of Type 2 Diabetes
Apples or Apple Pie: Helping Patients Make Healthy Changes
Possible Implications of Healthcare Reform on Diabetes Care
Type 2 Diabetes in Children and Adolescents
Interventions Targeting Impaired Glucose Tolerance
Are We Close to Development of an Artificial Pancreas?
Implications of the ACCORD, ADVANCE and VA Diabetes Trials
The International Diabetes Federation's Global Campaign
How Will Pharmacogenomics Play a Role in Diabetes Therapy?
DPP-4 Inhibitors: A New Class of Medications
The Importance of Diabetes Education for Patients and Providers
The Importance of Immunizations for Diabetic Patients
Create your
podcast in
minutes
It is Free
RenaissanceOnlineRadio.com
Men in Lead Aprons
Denver Underground
Exercise: Learn To Love (Or At Least Like) It
NASACast Video